水飞蓟宾葡甲胺盐对肝纤维化大鼠的疗效和可能机制

发布时间：2018-08-01 16:16

【摘要】：目的:考察水飞蓟宾葡甲胺盐对肝纤维化大鼠的疗效和可能机制。方法:将肝纤维化大鼠相随机分为4个组别,即模型组、水飞蓟宾葡甲胺盐高剂量组120 mg/kg、水飞蓟宾葡甲胺盐中剂量组60 mg/kg和水飞蓟宾葡甲胺盐低剂量组30 mg/kg,将同期正常大鼠作为正常对照组,每组10只,连续给药4周。结果:试验全程无死亡大鼠。与正常组比,模型组大鼠体重减少,少动,毛发暗淡,肝脏指数减少(P0.05),脾脏指数增加(P0.05),与模型组相比,水飞蓟宾葡甲胺各组体重明显增加(P0.05),活动较好,毛发色泽有改善,肝脏指数明显增加(P0.05),脾脏指数明显降低(P0.05)。与对照组比,模型组的ALT、AST和TBIL增高(P0.05),ALB降低(P0.05),与模型组相比,水飞蓟宾葡甲胺各组的ALT、AST和TBIL显著降低(P0.05),ALB显著增高(P0.05)。与对照组比,模型组的TG、TC和LDLC增高(P0.05),与模型组相比,水飞蓟宾葡甲胺各组的TG、TC和LDLC显著降低(P0.05)。与对照组相比,模型组的LXRα及SREBP1c蛋白显著增高(P0.05),与模型组相比,水飞蓟宾葡甲胺各组的LXRα及SREBP1c蛋白显著降低(P0.05)。模型组大鼠的肝小叶消失,中度增生的显微组织将肝小叶分为不同的假小叶,大部分肝细胞明显脂肪变性,点灶状坏死,水飞蓟宾葡甲胺各组的肝组织,肝小叶恢复,肝细胞脂肪变性改善,坏死点灶明显减少。结论:水飞蓟宾葡甲胺盐具有治疗肝纤维化的作用,在改善肝功能和降低血脂方面具有显著优势,与降低肝组织的LXRα和SREBP1c表达有关,但降低上述两种蛋白的机理仍有待进一步考察。
[Abstract]:Aim: to investigate the therapeutic effect and possible mechanism of silybin meglumine on hepatic fibrosis in rats. Methods: rats with hepatic fibrosis were randomly divided into 4 groups: model group. The rats in the high dose group (120 mg / kg), the middle dose group (60 mg/kg) and the low dose group (30 mg / kg) were treated with 10 rats in each group for 4 weeks. Results: there were no dead rats in the whole course of the experiment. Compared with the normal group, the rats in the model group lost weight, moved less, lost the hair, decreased the liver index (P0.05), increased the spleen index (P0.05), compared with the model group, the body weight of silybin meglumide group increased significantly (P0.05), the activity was better, the hair color and luster were improved. Liver index increased significantly (P0.05), spleen index decreased significantly (P0.05). Compared with the control group, the alt AST and TBIL in the model group increased (P0.05) and the ALB decreased (P0.05). Compared with the model group, the alt AST and TBIL in silybin meglumine group were significantly lower (P0.05). Compared with the control group, the TGTC and LDLC in the model group were significantly higher than those in the model group (P0.05), and the levels of TGTC and LDLC in the silybin meglumide group were significantly lower than those in the model group (P0.05). Compared with the control group, the LXR 伪 and SREBP1c protein in the model group increased significantly (P0.05), and the LXR 伪 and SREBP1c protein decreased significantly in the silybin meglumine group compared with the model group (P0.05). In the model group, the hepatic lobule disappeared, the moderately proliferated microstructures divided the hepatic lobules into different pseudolobules, most of the liver cells were obviously steatosis, focal necrosis, silybin meglumide group liver tissue, hepatic lobule recovery. Fatty degeneration of hepatocytes was improved, and necrosis sites were decreased obviously. Conclusion: silybin meglumine has a significant advantage in improving liver function and lowering blood lipids, which is related to the decrease of LXR 伪 and SREBP1c expression in liver tissue. However, the mechanism of reducing the two proteins remains to be further investigated.
【作者单位】：黔南民族医学高等专科学校;
【基金】：黔南民族医学高等专科学校科研基金项目(No.QNYZ 2013字2号)
【分类号】：R575.2

【相似文献】